StageZero Life Sciences Gestion

Gestion contrôle des critères 2/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

James Howard-Tripp

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	8.2yrs
Propriété du PDG	0.2%
Durée moyenne d'occupation des postes de direction	pas de données
Durée moyenne du mandat des membres du conseil d'administration	16.4yrs

Mises à jour récentes de la gestion

Recent updates

Imagine Holding StageZero Life Sciences (TSE:SZLS) Shares While The Price Zoomed 465% Higher

Jan 25

PDG

James Howard-Tripp

8.2yrs

Titularisation

US$270,000

Compensation

Mr. James R. Howard-Tripp has been the Executive Chairman of StageZero Life Sciences Ltd. (formerly known as GeneNews Limited) (also known as ChondroGene Ltd.) since July 12, 2013 and has been its Chief Ex...

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
James Howard-Tripp	Executive Chairman & CEO	22.8yrs	US$270.00k	0.19% CA$ 9.3k
Rory Riggs	Independent Director	24.8yrs	US$40.00k	10.15% CA$ 501.7k
Garth A. MacRae	Independent Director	24.4yrs	US$40.00k	0.12% CA$ 5.9k
Lawrence Cohen	Member of Colorectal Cancer Clinical Advisory Board	15.9yrs	pas de données	pas de données
David Sidransky	Member of Colorectal Cancer Clinical Advisory Board	no data	pas de données	pas de données
Khursheed Jeejeebhoy	Member of Colorectal Cancer Clinical Advisory Board	15.9yrs	pas de données	pas de données
Harry Glorikian	Independent Director	16.4yrs	US$40.00k	0.087% CA$ 4.3k
Richard Wender	Member of Colorectal Cancer Clinical Advisory Board	no data	pas de données	pas de données
Bernard Levin	Chairman of Colorectal Cancer Clinical Advisory Board	17.3yrs	pas de données	pas de données
David Lieberman	Member of Colorectal Cancer Clinical Advisory Board	no data	pas de données	pas de données
Barry Stein	Member of Colorectal Cancer Clinical Advisory Board	15.9yrs	pas de données	pas de données
Jeffrey Baker	Member of Colorectal Cancer Clinical Advisory Board	15.9yrs	pas de données	pas de données

16.4yrs

Durée moyenne de l'emploi

71yo

Âge moyen

Conseil d'administration expérimenté: Le conseil d'administration de la SZLS est chevronné et expérimenté ( 16.4 années d'ancienneté moyenne).

StageZero Life Sciences Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Insufficient new directors

Insufficient new directors

Stagezero Life Sciences Ltd. Announces Resignation of Matthew Pietras as COO

Insufficient new directors

StageZero Life Sciences Ltd., Annual General Meeting, Jun 28, 2022

StageZero Life Sciences Ltd., Annual General Meeting, May 17, 2021

Recent updates

Insufficient new directors

StageZero Life Sciences Ltd. to Report Q4, 2023 Results on May 31, 2024

New major risk - Share price stability

Third quarter 2023 earnings released: US$0.01 loss per share (vs US$0 in 3Q 2022)

StageZero Life Sciences, Ltd. Clinical Business Introduces Fourth Pillar to Cancer Offerings

New major risk - Share price stability

Stagezero Life Sciences, Ltd. Clinical Business Introduces Third Pillar to Cancer Offerings

Second quarter 2023 earnings released: US$0.003 loss per share (vs US$0.013 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.02 loss per share (vs US$0.006 loss in 1Q 2022)

StageZero Life Sciences Ltd. to Report Q1, 2023 Results on May 15, 2023

Third quarter 2022 earnings released: EPS: US$0 (vs US$0.033 loss in 3Q 2021)

Insufficient new directors

StageZero Life Sciences Ltd. to Report Q3, 2022 Results on Nov 15, 2022

StageZero Life Sciences Ltd. announced that it has received CAD 0.177 million in funding

Second quarter 2022 earnings released: US$0.01 loss per share (vs US$0.067 profit in 2Q 2021)

StageZero Life Sciences Ltd. to Report Q2, 2022 Results on Aug 16, 2022

Stagezero Life Sciences Ltd. Announces Resignation of Matthew Pietras as COO

First quarter 2022 earnings released: US$0.01 loss per share (vs US$0.12 loss in 1Q 2021)

StageZero Life Sciences Ltd. to Report Q1, 2022 Results on May 17, 2022

Insufficient new directors

StageZero Life Sciences Ltd., Annual General Meeting, Jun 28, 2022

Full year 2021 earnings released: US$0.11 loss per share (vs US$0.15 loss in FY 2020)

StageZero Life Sciences Ltd. Launches AVRT Program for Patients Living in the United Kingdom

StageZero Life Sciences Ltd. to Report Q4, 2021 Results on Apr 01, 2022

StageZero Life Sciences Ltd. to Report Q4, 2021 Results on Apr 01, 2022

StageZero Life Sciences Ltd. announced that it has received CAD 1.87 million in funding

StageZero Life Sciences Ltd. announced that it expects to receive CAD 1.87 million in funding

StageZero Life Sciences Ltd. announced that it has received CAD 4.200001 million in funding

StageZero Life Sciences Ltd. announced that it expects to receive CAD 4.200001 million in funding

Third quarter 2021 earnings released: US$0.02 loss per share (vs US$0.11 loss in 3Q 2020)

StageZero Life Sciences Ltd. (TSX:SZLS) completed the acquisition of All Assets of Health Clinics Limited and Health Clinics USA Corp.

Interim Chief Financial Officer Carl Solomon has left the company

Second quarter 2021 earnings released: EPS US$0.05 (vs US$0.006 loss in 2Q 2020)

Stagezero Life Sciences Offers Drive-Up, COVID-19 PCR Travel Testing with Results Reported the Same Day

First quarter 2021 earnings released

Full year 2020 earnings released

StageZero Life Sciences Ltd., Annual General Meeting, May 17, 2021

New 90-day high: CA$1.45

Imagine Holding StageZero Life Sciences (TSE:SZLS) Shares While The Price Zoomed 465% Higher

New 90-day high: CA$0.92

New 90-day low: CA$0.63

StageZero Life Sciences Ltd. has completed a Composite Units Offering in the amount of CAD 10.000068 million.

StageZero Life Sciences Ltd. to Report Q3, 2020 Results on Nov 18, 2020

StageZero Life Sciences Ltd. to Provide Rapid Testing Services for Travelers from U.S. and Canada

StageZero Life Sciences Ltd. Launches Saliva PCR Testing for the Detection of the SARS-COV-2 Virus

New 90-day high: CA$0.87

First half earnings released

StageZero Life Sciences Ltd. to Report Q2, 2020 Results on Aug 14, 2020

StageZero Life Sciences Ltd. has completed a Composite Units Offering in the amount of CAD 4.632327 million.

PDG

Titularisation

Compensation

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen